SEC Form 4 · accession 0001209191-18-002497
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shao-Lee Lin
Officer — EVP, Head of R&D and CSO
Period of report
Jan 4, 2018
Accepted (ET)
Jan 5, 2018 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.37 | Jan 4, 2018 | A | 146,685 | A | — | Jan 3, 2028 | Ordinary shares | 146,685 | 146,685 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 4, 2018 | A | 71,567 | A | — | — | Ordinary shares | 71,567 | 71,567 | D |
Explanation of responses
- F125% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F3The shares subject to the restricted stock units shall vest in four equal annual installments, beginning on the first anniversary of the grant date.